By using immune cells called dendritic cells to deliver drugs, it is possible to target and kill specific members of another class of immune cell, known as T cells, and to prevent these cells from attacking the body's own tissues in cases of autoimmune disease.

Inner-ear drug delivery experiments show that the fluids in the cochlea circulate due to the peristaltic action of motile auditory receptor cells.

Engineered local heterogeneity in drug concentration is used as a tool to encode drug treatment regimens and to predict the macroscopic cellular response to drug perturbations.

Stimuli signaling reward availability potentiate and control relapse for up to 300 days of abstinence following cocaine, but not food, self-administration in rats.

Non-native synthetic short-chain glycosphingolipids fused to GLP-1 enable intestinal absorption with high bioavailability in vivo.

The novel PDLIM2 nanomedicine enhances chemoimmunotherapy for complete cure of lung cancer.

Studies of the substrate selectivity of concentrative nucleoside transporters provide proof of principle for structure-based improvement of drug delivery by these transporters.

Pooled CRISPR knockout screening in Drosophila cells enables high-resolution, genome-wide functional genomic comparisons in cell-lines across vast evolutionary distance.

The combination of in vitro investigations, the zebrafish screening model and rodent experiments offered a unique approach to optimizing nanoparticles modified with Hepatitis B virus-derived peptides to specifically target hepatocytes.

Dopamine signaling in the bed nucleus of stria terminalis supports sign-tracking, reinforcer-specific satiety, and encodes reward prediction errors.